Immune checkpoint inhibitor-associated myocarditis and fulminant type I diabetes in a patient with metastatic non-small cell lung cancer

• Published in: BMJ case reports Vol. 16; no. 8; p. e255698
• Main Authors: Davis, Brandon Matthew, Fordjour, Isaac, Chahin, Michael, Guha, Avirup
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 16.08.2023
• Subjects: Apoptosis; Biomarkers; Blood pressure; Cancer therapies; Carcinoma, Non-Small-Cell Lung - complications; Carcinoma, Non-Small-Cell Lung - drug therapy; Cardiac arrhythmia; Cardiomyopathy; Cardiovascular disease; Case reports; Diabetes; Diabetes Mellitus, Type 1 - chemically induced; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - drug therapy; Diabetic Ketoacidosis - complications; Drug dosages; Dyspnea; Endocrinology; Female; Heart failure; Heart rate; Hematology; Humans; Hypothyroidism; Immune Checkpoint Inhibitors - therapeutic use; Insulin; Ischemia; Lung cancer; Lung Neoplasms - complications; Lung Neoplasms - drug therapy; Metastasis; Myocarditis - complications; Oncology; Peptides; Steroids; Thrombosis; Toxicity; Ultrasonic imaging; Diabetes; Immunological products and vaccines; Cardiovascular medicine; Lung cancer (oncology)

A woman in her mid-60s presented to the hospital due to a history of nausea, vomiting, shortness of breath, dyspnoea on exertion and polyuria. She was receiving medical therapy for advanced non-small cell lung cancer and recently initiated immune checkpoint inhibitor (ICI) immunotherapy. Investigati...